Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships
Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management. Dr. Scanlon also says that there is a lot of variation in the cost and quality of care in oncology. The goal is to identify the appropriate payments for quality care.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
The antibody, an inhibitor of the enzyme lysyl oxidase-like-2, combined with gemcitabine, did not have a significant effect on progression-free survival compared to the placebo with gemcitabine arm, in pancreatic cancer patients.
The results of a phase 1b study, presented at the AACR special conference "Targeting the PI3K-mTOR Network in Cancer," found that Alpelisib could overcome resistance to the anti-EGFR antibody cetuximab, and the two regimens together were quite beneficial.
Research presented at the 56th Annual Meeting of the American Society for Radiation Oncology identified VEGF-A and TGF-beta as markers of treatment decision in patients with esophageal squamous cell carcinoma.